The Cure SMA Clinical Trial Experience Survey: A Study of Trial Participant Perspectives on Clinical Trial Management and Patient-Centric Management Practices

Overview

Journal Neurol Ther

Publisher Springer

Specialty Neurology

Date 2022 May 31

PMID 35635603

Authors

Ilse S Peterson

Allison J Mazzella

Lisa T Belter

Mary A Curry

Rosangel E Cruz

Jill Jarecki

Affiliations

Soon will be listed here.

Abstract

Introduction: Understanding clinical trial experiences can illuminate opportunities to optimize trial design and management, with potential benefits for recruitment and retention. This study sought to better understand clinical trial participant experiences and attitudes within spinal muscular atrophy (SMA), and how the evolving treatment landscape and participant characteristics may predict attitudes.

Methods: A survey was developed following a review of published literature and discussions with caregivers of SMA trial participants. This was distributed via email to known trial participants in Cure SMA's database, announcements in Cure SMA's newsletter, and emails to SMA clinical trial principal investigators.

Results: Seventy complete surveys reflecting unique clinical trial experiences were included in analysis. Responses revealed positive attitudes about clinical trial management overall. Top motivators for trial participation included clinical benefit, investigational drug access, and the opportunity to help others. Top concerns were safety, whether benefits would justify risks, and concerns about pain accompanying tests. The greatest stressors were fear of pain, adverse event concerns, and challenges managing medical complications of SMA. Top benefits of trial participation were hope for a better future, helping others, and relationships with the study team. In regression analysis, participant gender, age, and race all emerged as significant predictors (p < 0.05) of motivators, concerns, stressors, and benefits, as did respondent type, knowledge about SMA, distance to the trial site, and treatment era. Top recommendations for improving study management all related to receiving more information.

Conclusion: This research provides new perspective on patient experiences in SMA clinical trials. It underscores the importance of information and efforts to anticipate and accommodate participant needs. These findings may inform study design and interactions with research participants. They may become especially important in supporting recruitment and retention as more treatment options become available.

Citing Articles

Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation.

McNiff M, Hawkins S, Haase B, Bullivant J, McIver T, Mitelman O J Neuromuscul Dis. 2024; 11(2):459-472.

PMID: 38277300 PMC: 10977383. DOI: 10.3233/JND-230171.

References

Wirth B, Herz M, Wetter A, Moskau S, Hahnen E, Rudnik-Schoneborn S . Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet. 1999; 64(5):1340-56. PMC: 1377870. DOI: 10.1086/302369. View

Zerres K, Rudnik-Schoneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I . A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997; 146(1):67-72. DOI: 10.1016/s0022-510x(96)00284-5. View

Verhaart I, Robertson A, Wilson I, Aartsma-Rus A, Cameron S, Jones C . Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017; 12(1):124. PMC: 5496354. DOI: 10.1186/s13023-017-0671-8. View

Lamberti M, Awatin J . Mapping the Landscape of Patient-centric Activities Within Clinical Research. Clin Ther. 2017; 39(11):2196-2202. DOI: 10.1016/j.clinthera.2017.09.010. View

Wirth B, Brichta L, Schrank B, Lochmuller H, Blick S, Baasner A . Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006; 119(4):422-8. DOI: 10.1007/s00439-006-0156-7. View

Kolb S, Kissel J . Spinal Muscular Atrophy. Neurol Clin. 2015; 33(4):831-46. PMC: 4628728. DOI: 10.1016/j.ncl.2015.07.004. View

Greenberg R, Corneli A, Bradley J, Farley J, Jafri H, Lin L . Perceived barriers to pediatrician and family practitioner participation in pediatric clinical trials: Findings from the Clinical Trials Transformation Initiative. Contemp Clin Trials Commun. 2018; 9:7-12. PMC: 5898553. DOI: 10.1016/j.conctc.2017.11.006. View

Peay H, Tibben A, Fisher T, Brenna E, Biesecker B . Expectations and experiences of investigators and parents involved in a clinical trial for Duchenne/Becker muscular dystrophy. Clin Trials. 2013; 11(1):77-85. PMC: 3935382. DOI: 10.1177/1740774513512726. View

Kearney A, Rosala-Hallas A, Bacon N, Daykin A, Shaw A, Lane A . Reducing attrition within clinical trials: The communication of retention and withdrawal within patient information leaflets. PLoS One. 2018; 13(10):e0204886. PMC: 6209179. DOI: 10.1371/journal.pone.0204886. View

10.

Chappuy H, Doz F, Blanche S, Gentet J, Pons G, Treluyer J . Parental consent in paediatric clinical research. Arch Dis Child. 2005; 91(2):112-6. PMC: 2082705. DOI: 10.1136/adc.2005.076141. View

11.

Kaye J, Curren L, Anderson N, Edwards K, Fullerton S, Kanellopoulou N . From patients to partners: participant-centric initiatives in biomedical research. Nat Rev Genet. 2012; 13(5):371-6. PMC: 3806497. DOI: 10.1038/nrg3218. View

12.

Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L . Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995; 80(1):155-65. DOI: 10.1016/0092-8674(95)90460-3. View

13.

Mendell J, Al-Zaidy S, Shell R, Arnold W, Rodino-Klapac L, Prior T . Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017; 377(18):1713-1722. DOI: 10.1056/NEJMoa1706198. View

14.

Kaye J, Whitley E, Lund D, Morrison M, Teare H, Melham K . Dynamic consent: a patient interface for twenty-first century research networks. Eur J Hum Genet. 2014; 23(2):141-6. PMC: 4130658. DOI: 10.1038/ejhg.2014.71. View

15.

Lentz J, Kennett M, Perlmutter J, Forrest A . Paving the way to a more effective informed consent process: Recommendations from the Clinical Trials Transformation Initiative. Contemp Clin Trials. 2016; 49:65-9. DOI: 10.1016/j.cct.2016.06.005. View

16.

Gainotti S, Turner C, Woods S, Kole A, McCormack P, Lochmuller H . Improving the informed consent process in international collaborative rare disease research: effective consent for effective research. Eur J Hum Genet. 2016; 24(9):1248-54. PMC: 4989211. DOI: 10.1038/ejhg.2016.2. View

17.

Arnold W, Kassar D, Kissel J . Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2014; 51(2):157-67. PMC: 4293319. DOI: 10.1002/mus.24497. View

18.

Sharma N . Patient centric approach for clinical trials: Current trend and new opportunities. Perspect Clin Res. 2015; 6(3):134-8. PMC: 4504054. DOI: 10.4103/2229-3485.159936. View

19.

Joseph P, Craig J, Caldwell P . Clinical trials in children. Br J Clin Pharmacol. 2013; 79(3):357-69. PMC: 4345947. DOI: 10.1111/bcp.12305. View

20.

Woolfall K, Shilling V, Hickey H, Smyth R, Sowden E, Williamson P . Parents' agendas in paediatric clinical trial recruitment are different from researchers' and often remain unvoiced: a qualitative study. PLoS One. 2013; 8(7):e67352. PMC: 3701006. DOI: 10.1371/journal.pone.0067352. View